OngoingEUCTR 2005-003156-35
This study is comparing Ziprasidon with Clozapine for people with with schizophrenia and cannabis abuse/dependency will be randomized to ziprasidone or clozapine treatment. Dose of medication and frequency of administration will be flexible and adjustab.
SchizophreniaOther
- Countries
- Germany
- Sponsor
- Department of Psychiatry and Psychotherapy (Cologne)
- Condition
- Schizophrenia
OngoingEUCTR 2008-005019-16
This study is comparing CLOZAPINE with OLANZAPINE for people with A multi-centre prospective, randomized, double blind designed study examining the effectiveness and costs of clozapine compared to olanzapine in with schizophrenia or related psychotic dis. Participants receive CLOZAPINE or OLANZAPINE and complete study visits and assessments.
SchizophreniaOther
- Countries
- Netherlands
- Sponsor
- AMC- academisch psychiatrisch centrum
- Condition
- Schizophrenia
OngoingEUCTR 2008-003623-23
This study is looking at whether CLOZAPINE compared with RISPERIDONE can help people with A randomized controlled trial comparing the effect of clozapine and risperidone on cannabis craving in cannabis abusing or dependent with schizophrenia. Specific cognitive tasks will be us.
SchizophreniaOther
- Countries
- Netherlands
- Sponsor
- Academisch medisch centrum, department of psychiatry
- Condition
- Schizophrenia
OngoingEUCTR 2006-000980-26
This study is looking at whether Abilify can help people with Schizophrenia. Participants receive the study medicine Abilify and complete study visits and assessments.
SchizophreniaOther
- Countries
- Spain
- Sponsor
- Fundación para la Investigación biomedica del Hospital Gregorio Marañon
- Condition
- Schizophrenia
OngoingEUCTR 2017-004834-26
This study is looking at whether clozapine can help people with Schizophrenia. Participants receive the study medicine clozapine and complete study visits and assessments.
SchizophreniaOther
- Countries
- Netherlands
- Sponsor
- Albert Schweitzer hospital
- Condition
- Schizophrenia
OngoingEUCTR 2022-001582-12
This study is comparing Abilify Maintena with Xeplion for people with First episode SZ-spectrum individuals or Adolescents, Under 18. Participants receive Abilify Maintena or Xeplion and complete study visits and assessments.
SchizophreniaOther
- Countries
- Spain
- Sponsor
- Consorcio Centro de Investigacion Biomedica en Red (CIBER)
- Condition
- Schizophrenia
CompletedEUCTR 2020-006062-36
This study is comparing Evenamide with placebo for people with Chronic schizophrenia or Elderly. Participants receive Evenamide or placebo and complete study visits and assessments.
SchizophreniaOther
- Countries
- Germany, Italy, Czech Republic, Spain, Romania, Hungary, Poland, Estonia, Latvia, View results
- Sponsor
- Newron Pharmaceuticals S.p.A.
- Condition
- Schizophrenia
OngoingEUCTR 2013-005399-16
This study is looking at whether ARIPIPRAZOLE compared with RISPERIDONE can help people with First episode drug-naïve of psychosis. Participants receive one of the study medicines, such as ARIPIPRAZOLE or RISPERIDONE, and complete study visits and assessments.
SchizophreniaOther
- Countries
- Spain
- Sponsor
- Dr. Benedicto Crespo. Servicio Psiquiatría. Hospital Universitario Marqués de Valdecilla/IDIVAL
- Condition
- Schizophrenia
CompletedEUCTR 2017-001447-12
This study is comparing Brexpiprazole with placebo for people with Schizophrenia or Adolescents, Under 18. Participants receive Brexpiprazole or placebo and complete study visits and assessments.
SchizophreniaOther
- Countries
- Hungary, Spain, Poland, Bulgaria, France, Italy, Romania, View results
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Condition
- Schizophrenia
CompletedEUCTR 2019-003343-29
This study is comparing Pimavanserin with placebo for people with Schizophrenia. Participants receive Pimavanserin or placebo and complete study visits and assessments.
SchizophreniaOther
- Countries
- Czech Republic, Poland, Hungary, Bulgaria, Spain, Lithuania, Italy, Croatia, View results
- Sponsor
- ACADIA Pharmaceuticals Inc.
- Condition
- Schizophrenia
OngoingEUCTR 2007-004857-27
This study is looking at whether Sertindol compared with Risperidon can help people with schizophrenic and healthy controls. Participants receive one of the study medicines, such as Sertindol or Risperidon, and complete study visits and assessments.
SchizophreniaOther
- Countries
- Germany
- Sponsor
- Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University Munich
- Condition
- Schizophrenia
TerminatedEUCTR 2016-003435-38
This study is looking at whether Pimavanserin can help people with Schizophrenia. Participants receive the study medicine Pimavanserin and complete study visits and assessments.
SchizophreniaOther
- Countries
- Hungary, Spain, Bulgaria, Czech Republic, Germany, Lithuania, Poland, Italy, Croatia, View results
- Sponsor
- ACADIA Pharmaceuticals Inc.
- Condition
- Schizophrenia
OngoingEUCTR 2020-003745-11
This study is looking at whether None yet can help people with Schizophrenia. Participants receive the study medicine None yet and complete study visits and assessments.
SchizophreniaOther
- Countries
- France, Czech Republic, Spain, Slovakia, Hungary, Norway, Denmark, Lithuania, Italy, Greece, Belgium, Sweden, Netherlands, Finland, Croatia, Austria, Bulgaria, Portugal, Romania
- Sponsor
- Boehringer Ingelheim
- Condition
- Schizophrenia
OngoingEUCTR 2007-004528-19
This study is comparing QUETIAPINE with FLUPENTIXOL for people with schizophrenia. Participants receive QUETIAPINE or FLUPENTIXOL and complete study visits and assessments.
SchizophreniaOther
- Countries
- Germany, View results
- Sponsor
- University of Wuerzburg
- Condition
- Schizophrenia
OngoingEUCTR 2012-005435-87
This study is comparing ACETYLCYSTEINE with placebo for people with with early onset psychotic episodes or Adolescents, Under 18. Participants receive ACETYLCYSTEINE or placebo and complete study visits and assessments.
SchizophreniaOther
- Countries
- Spain
- Sponsor
- Fundación para la Investigación Biomédica Hospital Gregorio Marañón
- Condition
- Schizophrenia
OngoingEUCTR 2016-004973-42
This study is looking at care and outcomes for people with attenuated psychosis syndrome or Adolescents, Under 18. Some participants may receive placebo instead of the study treatment, and direct benefit is not guaranteed.
SchizophreniaOther
- Countries
- United Kingdom, View results
- Sponsor
- Boehringer Ingelheim Limited
- Condition
- Schizophrenia
OngoingEUCTR 2016-000118-31
This study is comparing Human normal immunoglobulin with placebo for people with Antibody associated Psychosis or Elderly. Participants receive Human normal immunoglobulin or placebo and complete study visits and assessments.
SchizophreniaOther
- Countries
- United Kingdom
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge
- Condition
- Schizophrenia
OngoingEUCTR 2019-003623-37
This study is comparing Cannabidiol (CBD) with placebo for people with Parkinson's disease psychosis or Elderly. Participants receive Cannabidiol (CBD) or placebo and complete study visits and assessments.
SchizophreniaOther
- Countries
- United Kingdom
- Sponsor
- King's College London [...] 1. King's College London 2. South London and Maudsley NHS Foundation Trust
- Condition
- Schizophrenia
CompletedEUCTR 2015-003503-39
This study is looking at care and outcomes for people with Individuals at Ultra High Risk for Psychosis or Adolescents, Under 18. Some participants may receive placebo instead of the study treatment, and direct benefit is not guaranteed.
SchizophreniaOther
- Countries
- Netherlands, Austria, Italy, Spain, Germany, United Kingdom
- Sponsor
- University Medical Center Utrecht
- Condition
- Schizophrenia
OngoingEUCTR 2022-001515-10
This study is comparing Trospium chloride with placebo for people with Psychosis Associated with Alzheimer’s Disease Dementia or Elderly. Participants receive Trospium chloride or placebo and complete study visits and assessments.
SchizophreniaOther
- Countries
- Spain, Slovakia, France, Italy, Bulgaria, Germany
- Sponsor
- Karuna Therapeutics
- Condition
- Schizophrenia
OngoingEUCTR 2017-002227-13
This study is comparing Pimavanserin with placebo for people with Hallucinations and Delusions Associated With Dementia-related Psychosis or Elderly. Participants receive Pimavanserin or placebo and complete study visits and assessments.
SchizophreniaOther
- Countries
- United Kingdom, Czech Republic, Slovakia, Bulgaria, Spain, Poland, France, Italy, View results
- Sponsor
- ACADIA Pharmaceuticals Inc.
- Condition
- Schizophrenia
CompletedNCT07549581
This study assessed the safety and pharmacology of SEP-380135 in adults living with schizophrenia or a major depressive episode linked to bipolarity or major depressive disorder. The registry now lists the study as completed.
DepressionOtherFrom 18 Years to 55 Years
- Countries
- United States
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Condition
- Depression
RecruitingISRCTN52338801
This feasibility trial is preparing to test psychodynamic interpersonal therapy for people experiencing psychosis. The ISRCTN record lists it as not yet recruiting.
SchizophreniaOtherFrom 18 Years to 100 Years
- Countries
- United Kingdom
- Sponsor
- Greater Manchester Mental Health NHS Foundation Trust
- Condition
- Schizophrenia
Not Yet RecruitingISRCTN11089633
This study will test Social Recovery Therapy for people living with psychosis and social disability. The ISRCTN record shows it as not yet recruiting.
SchizophreniaOtherFrom 18 Years to 65 Years
- Countries
- United Kingdom
- Sponsor
- Sussex Partnership NHS Foundation Trust
- Condition
- Schizophrenia
OngoingEUCTR 2021-004049-19
This EU CTR study is testing sodium oxybate for catatonia in adults living with depression, bipolarity, or psychotic disorders. The registry page currently marks the Dutch protocol as transitioned, which the app maps to ongoing.
DepressionOther
- Countries
- Netherlands
- Sponsor
- Amsterdam UMC
- Condition
- Depression